Trump’s Tariff Gambit Could Hurt Canadian Industry—But Hurt Americans Even More

Just when we thought we’d seen it all in cross-border trade tensions, U.S. President Donald Trump is back with another round of tariff threats—this time targeting copper and pharmaceuticals. The proposed measures—a 50% tariff on copper imports and a staggering 200% on pharmaceuticals—are raising eyebrows on both sides of the border. And while Canada may ultimately dodge the worst of it, the uncertainty alone is already a drag on our industries and economy.

Industry Minister Mélanie Joly struck a familiar tone this week: no executive order has been signed, but Canada is watching closely. With key negotiations between Trump and Canadian envoy Mark Carney ongoing and a July 21 deadline for a new trade and security deal, Ottawa is playing it smart by staying quiet. But behind closed doors, the concern is very real.

Copper is one of Canada’s key exports to the U.S., with over $4.5 billion shipped south in 2023 alone. Nearly half of our copper production comes from British Columbia, making the province particularly vulnerable to sudden U.S. policy swings. Should Canada be included in the tariffs, it could hit local miners and smelters hard—especially smaller operators who don’t have the luxury of pivoting to other markets.

But there’s another side to this coin. If Canada is exempted, as many experts hope, we might actually stand to benefit. Global copper prices would likely spike, and as a trusted U.S. supplier, Canadian producers could gain market share. That said, banking on exemptions from Trump’s White House is risky business. We’ve been burned before—just look at the steel and aluminum tariffs.

Then there’s the pharmaceutical angle, which is even more alarming. A 200% tariff on drug imports is more than just tough talk—it’s reckless. Canadian pharmaceutical exports, particularly generics, are deeply embedded in the U.S. healthcare system. According to estimates, $3 billion worth of U.S. pharmaceuticals depend on Canadian manufacturing, with tariffs potentially adding $750 million in costs.

While this would certainly hurt Canadian manufacturers, especially in Ontario and Quebec, the real losers would be American patients. We’re talking about drug shortages, higher premiums, and increased medical costs—a nightmare scenario for everyday Americans. It’s worth remembering: tariffs don’t create supply chains—they disrupt them. And in healthcare, disruptions can be deadly.

The Canadian Chamber of Commerce put it plainly, warning against the “tariff roller-coaster” that continues to destabilize critical North American supply chains. As Canadians, we have every reason to be concerned—but also to stay strategic. Canada remains a reliable, rule-abiding trade partner, and our long-term strength lies in that consistency.

Let’s be clear: Trump’s tariff threats aren’t about fair trade—they’re about political optics. They’re designed to score points at rallies, not solve real economic problems. And they threaten to hurt the very people they’re supposed to protect.

In the coming days, Canadian negotiators will have to walk a fine line: defending our interests without escalating tensions. If done right, Canada may emerge stronger. But if this tariff storm continues unchecked, we’ll all be paying the price—just some more than others.